retatrutide nafld nonalcoholic fatty liver disease nash trial Retatrutide, the triple G, Glucagon-GIP-GLP-1 based triagonist produces substantial resolution of liver fat #NAFLD in PPL with #obesity #ADA2023 @ADA_DiabetesPro @AmDiabetesAssn #NASH trial coming Retatrutide Clears Fatty Liver Disease

The next day, samples were incubated with Alexa Fluor 488-conjugated anti-IgG secondary antibodies and Alexa Fluor 647-conjugated anti-IgG for 1 h and stained with DAPI for 7 min

GIP receptor activation improves how the body processes and stores fat, enhances insulin sensitivity beyond what GLP-1 alone achieves, and appears to reduce the inflammatory signaling associated with excess adipose tissue

Targeted drug delivery (TDD) Targeted drug delivery stands as a meticulous approach, directing medication accurately to afflicted cells or tissues, thereby amplifying their therapeutic impact while mitigating adverse effects on healthy cells or tissues [168, 169]

A.Abu-QatousehL